ライフサイエンスコーパス: lichen planus

1 in D/VDR signaling induces miR-27a/b in oral lichen planus.

2 , 2011, of patients with a diagnosis of otic lichen planus.

3 t that LS does not affect the vagina, unlike lichen planus.

4 sentation, diagnosis, and management of otic lichen planus.

5 prototypic skin disease in this category is lichen planus.

6 onsible for the prototypic LTR/IFD disorder, lichen planus.

7 2-induced apoptosis of keratinocytes in oral lichen planus.

8 s had oral lesions that clinically resembled lichen planus.

9 y show persistent signs and symptoms of oral lichen planus.

10 cts or in subjects with atopic dermatitis or lichen planus.

11 jects with psoriasis, atopic dermatitis, and lichen planus.

12 rythematosus, alopecia areata, vitiligo, and lichen planus.

13 (P = .04) and oral mucosal disorders such as lichen planus.

14 throplakia, oral submucous fibrosis, or oral lichen planus.

15 efficacy and safety profile in treating nail lichen planus.

16 be a therapeutic approach for treating nail lichen planus.

17 The differential diagnosis includes lichen planus, a drug-related reaction, and viral infect

18 al different disease processes, particularly lichen planus and benign mucous membrane pemphigoid.

19 n and immune response in common between Oral Lichen Planus and early and advanced Oral Squamous Cell

20 presentation pathways in common between Oral Lichen Planus and early Oral Squamous Cell Carcinoma.

21 va were collected from 25 patients with oral lichen planus and from 25 age- and sex-matched controls.

22 as DG, although the two more common are oral lichen planus and mucous membrane pemphigoid.

23 lyzed the gene expression signatures of Oral Lichen Planus and Oral Squamous Cell Carcinoma in early

24 ate similarities in the gene profile of Oral Lichen Planus and Oral Squamous Cell Carcinoma that may

25 ucosal inflammatory diseases, including oral lichen planus and recurrent aphthous stomatitis, are pai

26 s do not support an association between oral lichen planus and salivary dysfunction in otherwise heal

27 patients with OSCC-R, and patients with oral lichen planus and served as a characteristic biomarker o

28 ases were associated with biopsy-proven oral lichen planus, and all five patients had oral lesions th

29 of HCV-infected patients had PCT, vitiligo, lichen planus, and cryoglobulinemia.

30 l in the treatment of oral leukoplakia, oral lichen planus, and head and neck cancer.

31 CC in remission (OSCC-R), patients with oral lichen planus, and healthy controls (HCs)-using a genome

32 eous inflammatory conditions, including oral lichen planus, are common, but development of new treatm

33 o, cutaneous lupus erythematosus, psoriasis, lichen planus, autoimmune bullous diseases, systemic scl

34 Otic lichen planus can lead to persistent hearing loss and sh

35 an increasingly prevalent form of follicular lichen planus, causing irreversible hair loss predominan

36 flammatory skin diseases (atopic dermatitis, lichen planus, contact eczema, and healthy controls).

37 The clinical diagnosis of lichen planus correlated with the biopsy findings in 80%

38 Only 1 patient with oral lichen planus developed oral cancer after 5 years.

39 orrheic dermatitis," "alopecia areata," and "lichen planus." Diverse study populations were defined a

40 tudies have reported new-onset psoriasis and lichen planus following TNFalpha antagonist therapy.

41 unity in GS was uncommon, consisting of oral lichen planus, graft-vs-host disease-like colitis, and p

42 ature to support the position that true oral lichen planus has no inherent predisposition to become m

43 Nail lichen planus has the potential to cause permanent destr

44 udy was undertaken to determine whether oral lichen planus in otherwise healthy patients is associate

45 Lichen planus is a dermatologic disease that affects bot

46 Lichen planus is an autoimmune inflammatory dermatosis t

47 rrounding the premalignant potential of oral lichen planus is provided with evidence, rationale, and

48 hroplakia, oral submucous fibrosis, and oral lichen planus-is crucial for early detection and improve

49 R, 0.703; 95% CI, 0.497-0.994; P = .045) and lichen planus/lichenoid dermatitis (HR, 0.511; 95% CI, 0

50 ogy confirmed the clinical diagnosis of oral lichen planus-like c-GVHD.

51 .1%) shows promise in the management of oral lichen planus-like c-GVHD.

52 were squamous cell carcinoma, 39 (8.5%) were lichen planus-like keratosis, 21 (4.6%) were melanomas,

53 lanocytic lesions (eg, seborrheic keratosis, lichen planus-like keratosis, basal cell carcinomas) mis

54 ding solar lentigo, seborrheic keratosis and lichen planus-like keratosis; dermatofibroma; melanoma;

55 se report we describe the occurrence of oral lichen planus-like lesions as the first manifestation of

56 phigus vulgaris, mucous membrane pemphigoid, lichen planus, linear immunoglobulin A disease, and chro

57 BACKGROUNDCutaneous lichen planus (LP) is a recalcitrant, difficult-to-treat

58 Lichen planus (LP) is a T-cell-mediated inflammatory dis

59 ne involved in the pathogenesis of cutaneous lichen planus (LP).

60 ognition of the nonspecific symptoms of otic lichen planus may lead to prompt treatment and avoidance

61 limus cream in the treatment of oral erosive lichen planus (OELP).

62 Oral lichen planus (OLP) and recurrent aphthous stomatitis (R

63 Symptomatic oral lichen planus (OLP) can be challenging to treat.

64 the origin and development mechanism of oral lichen planus (OLP) with limited attention to the role o

65 fibrosis (OSF), eleven individuals with oral lichen planus (OLP), and ten healthy controls.

66 naling has been shown in the context of oral lichen planus (OLP), the molecular basis of its regulato

67 al specimens of patients suffering with oral lichen planus (OLP), the molecular mechanism of miR-27b

68 ents with chronic periodontitis (CP) or oral lichen planus (OLP).

69 as benign mucous membrane pemphigoid, 10 as lichen planus or lichenoid mucositis (LP), and one as pe

70 is study, 30 cases were diagnosed as erosive lichen planus or lichenoid mucositis; 29 cases were diag

71 ntaining polarized T-cells to replicate oral lichen planus pathogenesis.

72 gnificant differences were found between the lichen planus patients and the controls.

73 induced in the skin lesions of psoriasis and lichen planus patients.

74 al diagnoses not optimally supported on DIF: lichen planus, porphyria, and connective tissue disease.

75 d at relieving symptoms and controlling oral lichen planus progression is hampered by the lack of exp

76 ds alopecia areata, acne, atopic dermatitis, lichen planus, psoriasis, seborrheic dermatitis, and vit

77 porphyria cutanea tarda [PCT], vitiligo, and lichen planus); renal (membranous glomerulonephritis [GN

78 inflammatory diseases, including psoriasis, lichen planus, rheumatoid arthritis, and inflammatory bo

79 main outcome was posttreatment clinical nail lichen planus severity index, which was scored as clear,

80 ients, with an overall 35% reduction in nail lichen planus severity index.

81 l disease, type 2 diabetes, B-cell lymphoma, lichen planus, Sjogren's syndrome, porphyria cutanea tar

82 Here we report five cases of lichen planus that presented as the oral component of th

83 t association between HCV infection and PCT, lichen planus, vitiligo, cryoglobulinemia, membranoproli

84 Oral lichen planus was the most common disease presenting as

85 Oral lichen planus was the most common disease presenting as

86 hroplakia, oral submucous fibrosis, and oral lichen planus were identified using International Statis

87 Lesions with the impression of oral lichen planus were unlikely to be either dysplastic or m

88 tes 7 adult patients with biopsy-proven nail lichen planus who were treated with low-dose naltrexone

89 ing in cytotoxic dermatitis resembling human lichen planus within 4 weeks.